Brand Intelligence Graphcompany
Company Overview
About Edwards Lifesciences
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
Business Model & Competitive Advantage
Edwards Lifesciences' structural heart focus addresses the global epidemic of valvular heart disease — estimated 5 million Americans have severe aortic stenosis, with 250,000+ TAVR procedures performed annually and only 50% of eligible patients currently treated — through minimally invasive catheter-based valve replacement and repair that offers superior outcomes versus open-heart surgery for elderly, high-risk patients. The SAPIEN 3 Ultra RESILIA TAVR valve (Edwards' latest generation) achieves the 30-day clinical outcomes that made TAVR the standard of care for severe aortic stenosis in intermediate- and high-risk surgical patients — with ongoing clinical trials establishing TAVR in low-risk patients under 65. The EVOQUE tricuspid replacement system addresses the underserved tricuspid regurgitation market (1 million+ severe TR patients in the US with no effective percutaneous treatment option) — a market opportunity larger than TAVR at the time of its launch.
Competitive Landscape 2025–2026
In 2025, Edwards Lifesciences competes in structural heart disease devices and transcatheter valve therapy against Medtronic (NYSE: MDT, Evolut TAVR platform), Abbott Laboratories (NYSE: ABT, MitraClip/Tendyne mitral), and Boston Scientific (NYSE: BSX, Acurate TAVR) for structural heart procedure market share, clinical trial enrollment, and international TAVR penetration. The $4.2B Critical Care divestiture to BD eliminates a slower-growth, lower-margin business and focuses Edwards' capital allocation entirely on the high-growth structural heart market where it holds a commanding competitive position. The JenaValve acquisition enables Edwards to address aortic regurgitation (AR) patients previously excluded from TAVR — a potential $3B+ incremental market. The 2025 strategy under management focuses on TMTT commercial acceleration (EVOQUE tricuspid in Europe and US), TAVR growth through low-risk patient expansion, and JenaValve AR indication approval, while deploying the $4.2B Critical Care proceeds through buybacks and strategic acquisitions.
The Edwards Lifesciences Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Edwards Lifesciences's journey
Leadership Team
Meet the leaders behind Edwards Lifesciences
Bernard J. Zovighian
Bernard J. Zovighian became CEO and joined the Board of Directors in May 2023. He joined Edwards in 2015 and has held leadership roles across multiple business units including Surgical Structural Heart, TAVR, and TMTT. Prior to Edwards, he spent nearly 20 years at Johnson & Johnson in roles of increasing responsibility, including worldwide president of one of the company's divisions.
Scott B. Ullem
Scott B. Ullem has served as CFO since 2014, leading Edwards' global finance organization. He has executive responsibility for information technology, information security, risk management, indirect sourcing, and corporate services teams. He plays a critical role in the company's strategic planning and capital allocation decisions.
Dr. Todd J. Brinton
Dr. Todd J. Brinton has served as corporate vice president, advanced technology, and chief scientific officer since 2019. A practicing clinical cardiologist with deep ties to the medical technology community, Dr. Brinton was physician founder, board member, and chief medical officer of Shockwave Medical, which was acquired by Johnson & Johnson in 2024.
Daveen Chopra
Daveen Chopra joined Edwards Lifesciences in May 2018 and oversees the company's TMTT and Surgical businesses. She brings broad experience in the medical technology industry, with global leadership expertise in strategy, marketing, commercial operations, research and development, and program management.
Larry L. Wood
Larry Wood serves as group president of TAVR and Surgical Structural Heart, overseeing the company's largest revenue-generating business units. He has responsibility for the global commercial operations, product development, and strategic direction of Edwards' market-leading transcatheter and surgical valve portfolios.
Dr. Huimin Wang
Dr. Huimin Wang leads Edwards Lifesciences' operations across the Japan, Asia and Pacific regions, a critical growth market for the company's structural heart technologies. She is responsible for commercial strategy, regulatory affairs, and market development across this diverse geographic territory.
Key Differentiators
Market Leader
Edwards Lifesciences is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Edwards Lifesciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Edwards Lifesciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Edwards Lifesciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Edwards Lifesciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →